Cargando…

Human immunodeficiency virus-associated tuberculosis care in Botswana: evidence from a real-world setting

BACKGROUND: Tuberculosis (TB) is among the world’s top public health challenges and the leading killer of people with HIV, yet is a treatable disease. This study aimed to assess, in a real-world setting, the implementation of antiretroviral therapy (ART) and Cotrimoxazole preventive therapy (CPT) po...

Descripción completa

Detalles Bibliográficos
Autores principales: Muyaya, Ley Muyaya, Musanda, Esperance Manwana, Tamuzi, Jacques Lukenze
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720078/
https://www.ncbi.nlm.nih.gov/pubmed/31477055
http://dx.doi.org/10.1186/s12879-019-4401-9
_version_ 1783448047118712832
author Muyaya, Ley Muyaya
Musanda, Esperance Manwana
Tamuzi, Jacques Lukenze
author_facet Muyaya, Ley Muyaya
Musanda, Esperance Manwana
Tamuzi, Jacques Lukenze
author_sort Muyaya, Ley Muyaya
collection PubMed
description BACKGROUND: Tuberculosis (TB) is among the world’s top public health challenges and the leading killer of people with HIV, yet is a treatable disease. This study aimed to assess, in a real-world setting, the implementation of antiretroviral therapy (ART) and Cotrimoxazole preventive therapy (CPT) policy, specific interventions proven to benefit patients in HIV-associated TB care. METHODS: This retrospective cohort study was conducted in Botswana in the Serowe/Palapye district, a largely urban district with a high burden of HIV-associated TB with a high case fatality, at Segkoma and Palapye hospitals and their feeder clinics. Between 1 January 2013 and 31 December 2013, confirmed HIV-positive patients aged ≥15 years with a confirmed TB diagnosis and medical record available were included in the analysis. The Kaplan-Meier method was used to compare time to death for the group of patients on ART and the group of patients not on ART during TB treatment. Cox proportional hazard regression was undertaken to identify predictors of mortality. RESULTS: Of the 300 patients included in the study, 217 (72%) were ART experienced at TB diagnosis. Of these, 86 (40%) had TB within 3 months following ART initiation. Of the 83 (28%) patients who were ART-naïve at TB diagnosis, 40 (48%) were commenced on ART during TB treatment, with 24 (60%) patients commencing within 4 weeks following TB treatment initiation. The overall ART uptake was 84%, while cotrimoxazole preventive therapy uptake was 100%. There were 45 deaths (15%), ART-experienced patients during TB treatment accounted for 30 deaths (30/257; 14%), while those who were not ART-experienced during TB treatment accounted for 15 deaths (15/43; 35%). There was a significant difference in survival time between patients with no ART use during TB treatment and those with ART use during TB treatment (log rank p < 0.001). Patients with no ART use during TB treatment were more likely to die within the first 2 months. CONCLUSION: The implementation of CPT policy is a substantial success. Strengthening the implementation of ART policy could improve survival among HIV-associated TB patients.
format Online
Article
Text
id pubmed-6720078
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67200782019-09-06 Human immunodeficiency virus-associated tuberculosis care in Botswana: evidence from a real-world setting Muyaya, Ley Muyaya Musanda, Esperance Manwana Tamuzi, Jacques Lukenze BMC Infect Dis Research Article BACKGROUND: Tuberculosis (TB) is among the world’s top public health challenges and the leading killer of people with HIV, yet is a treatable disease. This study aimed to assess, in a real-world setting, the implementation of antiretroviral therapy (ART) and Cotrimoxazole preventive therapy (CPT) policy, specific interventions proven to benefit patients in HIV-associated TB care. METHODS: This retrospective cohort study was conducted in Botswana in the Serowe/Palapye district, a largely urban district with a high burden of HIV-associated TB with a high case fatality, at Segkoma and Palapye hospitals and their feeder clinics. Between 1 January 2013 and 31 December 2013, confirmed HIV-positive patients aged ≥15 years with a confirmed TB diagnosis and medical record available were included in the analysis. The Kaplan-Meier method was used to compare time to death for the group of patients on ART and the group of patients not on ART during TB treatment. Cox proportional hazard regression was undertaken to identify predictors of mortality. RESULTS: Of the 300 patients included in the study, 217 (72%) were ART experienced at TB diagnosis. Of these, 86 (40%) had TB within 3 months following ART initiation. Of the 83 (28%) patients who were ART-naïve at TB diagnosis, 40 (48%) were commenced on ART during TB treatment, with 24 (60%) patients commencing within 4 weeks following TB treatment initiation. The overall ART uptake was 84%, while cotrimoxazole preventive therapy uptake was 100%. There were 45 deaths (15%), ART-experienced patients during TB treatment accounted for 30 deaths (30/257; 14%), while those who were not ART-experienced during TB treatment accounted for 15 deaths (15/43; 35%). There was a significant difference in survival time between patients with no ART use during TB treatment and those with ART use during TB treatment (log rank p < 0.001). Patients with no ART use during TB treatment were more likely to die within the first 2 months. CONCLUSION: The implementation of CPT policy is a substantial success. Strengthening the implementation of ART policy could improve survival among HIV-associated TB patients. BioMed Central 2019-09-02 /pmc/articles/PMC6720078/ /pubmed/31477055 http://dx.doi.org/10.1186/s12879-019-4401-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Muyaya, Ley Muyaya
Musanda, Esperance Manwana
Tamuzi, Jacques Lukenze
Human immunodeficiency virus-associated tuberculosis care in Botswana: evidence from a real-world setting
title Human immunodeficiency virus-associated tuberculosis care in Botswana: evidence from a real-world setting
title_full Human immunodeficiency virus-associated tuberculosis care in Botswana: evidence from a real-world setting
title_fullStr Human immunodeficiency virus-associated tuberculosis care in Botswana: evidence from a real-world setting
title_full_unstemmed Human immunodeficiency virus-associated tuberculosis care in Botswana: evidence from a real-world setting
title_short Human immunodeficiency virus-associated tuberculosis care in Botswana: evidence from a real-world setting
title_sort human immunodeficiency virus-associated tuberculosis care in botswana: evidence from a real-world setting
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720078/
https://www.ncbi.nlm.nih.gov/pubmed/31477055
http://dx.doi.org/10.1186/s12879-019-4401-9
work_keys_str_mv AT muyayaleymuyaya humanimmunodeficiencyvirusassociatedtuberculosiscareinbotswanaevidencefromarealworldsetting
AT musandaesperancemanwana humanimmunodeficiencyvirusassociatedtuberculosiscareinbotswanaevidencefromarealworldsetting
AT tamuzijacqueslukenze humanimmunodeficiencyvirusassociatedtuberculosiscareinbotswanaevidencefromarealworldsetting